[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635738":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":50,"studyPopulation":11,"armGroups":51,"interventions":57,"overallOfficials":11,"centralContacts":67,"locations":77,"responsibleParty":93,"collaborators":11,"id":95,"slug":11,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":96,"sex":102,"minAge":103,"maxAge":11,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":109,"conditions":110,"keywords":11,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"XVIVO Perfusion","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Patient Survival",null,"30 days post-transplant",[14,16,19,22,24,27,29,31,34,37,39,41],{"measure":15,"description":11,"timeFrame":12},"Cardiac related mortality at 30 days post-transplant",{"measure":17,"description":11,"timeFrame":18},"Incidence of Mechanical circulatory support within 30 days post-transplant","30-days post-transplant",{"measure":20,"description":11,"timeFrame":21},"Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant","24 hours post-transplant",{"measure":23,"description":11,"timeFrame":21},"Incidence of Primary Graft Dysfunction (PGD) RV at 24 hours post-transplant",{"measure":25,"description":11,"timeFrame":26},"Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant","24 hours and 30 days post-transplant",{"measure":28,"description":11,"timeFrame":18},"Duration of initial ICU stay after the index procedure",{"measure":30,"description":11,"timeFrame":12},"Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime) within 30 days post-transplant",{"measure":32,"description":11,"timeFrame":33},"Incidence of hearts perfused on the investigational device which is not used for transplantation","From enrollment to the end of recruitment",{"measure":35,"description":11,"timeFrame":36},"Cardiac related mortality at 6 and 12 months post-transplant","6 and 12 months post-transplant",{"measure":38,"description":11,"timeFrame":36},"Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 6 and 12 months post-transplant",{"measure":40,"description":11,"timeFrame":36},"Number of days until hospital discharge from index procedure 6 and 12 months post-transplant",{"measure":42,"description":11,"timeFrame":43},"Incidence of biopsy proven rejections > 1 ACR leading to changed immunosuppressive regime within 12 months post-transplant","Within 12 months post-transplant",{"allocation":45,"interventionModel":46,"interventionModelDescription":11,"primaryPurpose":47,"observationalModel":11,"timePerspective":11,"maskingInfo":48},"NA","SINGLE_GROUP","TREATMENT",{"masking":49,"maskingDescription":11,"whoMasked":11},"NONE","HOPE for All will include a total of 20 subjects transplanted with donor hearts using the revised XVIVO Heart Assist Transport System and will evaluate transplant outcomes such as patient survival, post-transplant complications and graft function for a period of 12 months post-transplant.\n\nThe investigation will be conducted at 1 heart transplant center in Belgium who has thorough experience using the XVIVO Heart Assist Transport System for both DBD and DCD transplants.\n\nThe study will not include a control group as this is a proof-of-concept study",[52],{"label":53,"type":54,"description":11,"interventionNames":55},"Preservation of DBD and DCD hearts for transplant.","EXPERIMENTAL",[56],"Device: XVIVO Heart Assist Transport System",[58],{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"DEVICE","XVIVO Heart Assist Transport System","Revised XHAT",[53],[64,65,66],"Hypothermic oxygenated perfusion - HOPE","Direct procurment","Non-Ischemic Heart Preservation NIHP",[68,73],{"name":69,"role":70,"phone":71,"phoneExt":11,"email":72},"Filip Rega, MD, PhD","CONTACT","+32 16 34 08 43","filip.rega@uzleuven.be",{"name":74,"role":70,"phone":75,"phoneExt":11,"email":76},"Janne Brouckaert, MD","+3216346278","Janne.brouckaert@uzleuven.be",[78],{"facility":79,"status":80,"city":81,"state":11,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"UZ Leuven","RECRUITING","Leuven","B-3000","Belgium","BE",{"type":86,"coordinates":87},"Point",[88,89],4.70093,50.87959,{"lat":89,"lon":88},[92],{"name":69,"role":70,"phone":71,"phoneExt":11,"email":72},{"type":94,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635738",false,"NCT07556588","XVIVO Heart Transplant Study in Clinical Practice","Application of Hypothermic Oxygenated Perfusion in Donor Heart Preservation in Clinical Practice - HOPE for All","HOPE for All","Inclusion Criteria Recipient:\n\n1. Age ≥18 years\n2. Signed informed consent form\n3. Accepted or listed for heart transplantation\n\nInclusion Criteria Heart Donor:\n\n1. Accepted as a heart donor by the transplant team based on current standard of care criteria\n2. DBD or DCD Maastricht category III or euthanasia donors\n\nExclusion Criteria Recipient:\n\n1. Not able to understand the information provided during the informed consent procedure\n2. Combined organ transplantation candidates\n\nExclusion Criteria Heart Donor:\n\n1. Functional warm ischemia time (FWIT) \\> 30 minutes (DCD).\n2. Donor cardiac arrest does not occur within 120 minutes from Withdrawal of life sustaining therapy (DCD)\n3. Deviations from Donor end of life treatment protocol as defined by local standard operating procedures\n4. Donor heart assessed as not transplantable by the responsible clinician at any time point during the donation or procurement procedure","ALL","18 Years",{"count":105,"type":106},20,"ESTIMATED","INTERVENTIONAL",[45],"HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.\n\nThe trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient.\n\nThe hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation.\n\nPrimary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation.\n\nSecondary objective(s) are to evaluate patient outcomes and graft function post-transplant.\n\nHOPE for All is a prospective, single-armed single-centre proof-of-consept trial.",[111],"Heart Failure","2026-04-21",{"date":114,"type":115},"2026-04-29","ACTUAL",{"date":117,"type":106},"2026-04-15",{"date":119,"type":106},"2028-04-15",{"name":5,"class":6},1]